What's fueling the biotech engine?

A survey of market trends for biotech products shows that only a handful out of more than one hundred biologics have been fueling the double-digit rise in revenues in the sector.

[1]  J. Bausch,et al.  Monoclonal antibodies. , 1990, Bioprocess technology.

[2]  Jonathan Scott.  Uphill struggle , 1991, Nature.

[3]  Gary Walsh,et al.  Biopharmaceutical benchmarks , 2000, Nature Biotechnology.

[4]  S. Davidson.  Biogen, Serono squabble over MS market , 2001, Nature Biotechnology.

[5]  H. Miller.  As biotech turns 20... , 2002, Nature Reviews Drug Discovery.

[6]  Jean-Luc Wybo,et al.  11/9: a historical perspective , 2003 .

[7]  Deborah Schrag,et al.  The price tag on progress--chemotherapy for colorectal cancer. , 2004, The New England journal of medicine.

[8]  R. Glass,et al.  The future of rotavirus vaccines: a major setback leads to new opportunities , 2004, The Lancet.

[9]  A. Pavlou,et al.  Monoclonal antibodies market , 2004, Nature Reviews Drug Discovery.

[10]  C. Mount,et al.  Rheumatoid arthritis market , 2005, Nature Reviews Drug Discovery.

[11]  G. Anand.  Why Genzyme can charge so much for Cerezyme. , 2005, Wall Street journal.

[12]  P. Rosenfeld,et al.  Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. , 2005, Ophthalmology.

[13]  Gary Walsh,et al.  Biopharmaceutical benchmarks 2006 , 2006, Nature Biotechnology.

[14]  R. Steinbrook,et al.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration. , 2006, The New England journal of medicine.

[15]  P. Aurup,et al.  Off-Label Reports of New Biologics: Exciting New Therapy or Dubious Research? Examples From Recombinant Activated Factor VII , 2006, Journal of intensive care medicine.

[16]  G. Remuzzi,et al.  Correction of anemia--payoffs and problems. , 2006, The New England journal of medicine.

[17]  A. Abbott.  Lyme disease: Uphill Struggle , 2006, Nature.

[18]  Steven Kozlowski,et al.  The FDA's assessment of follow-on protein products: a historical perspective , 2007, Nature Reviews Drug Discovery.

[19]  R. Cohen,et al.  Calcinosis Associated with Renal Failure , 2007 .

[20]  K. Rother.  Diabetes treatment--bridging the divide. , 2007, The New England journal of medicine.

[21]  S. Opal.  Can we RESOLVE the treatment of sepsis? , 2007, The Lancet.

[22]  F. Khuri.  Weighing the hazards of erythropoiesis stimulation in patients with cancer. , 2007, The New England journal of medicine.

[23]  R. Frank.  Regulation of follow-on biologics. , 2007, The New England journal of medicine.

[24]  Janice M. Reichert,et al.  Development trends for monoclonal antibody cancer therapeutics , 2007, Nature Reviews Drug Discovery.